Leerink Partnrs Increases Earnings Estimates for AC Immune

AC Immune SA (NASDAQ:ACIU) – Equities research analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of AC Immune in a report issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of ($0.60) for the year, up from their prior forecast of ($0.81). The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.87) EPS and FY2028 earnings at $0.00 EPS.

Several other equities analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of AC Immune in a report on Wednesday. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st.

AC Immune Price Performance

NASDAQ:ACIU opened at $3.20 on Friday. AC Immune has a one year low of $2.25 and a one year high of $5.14. The business has a fifty day moving average price of $3.27 and a 200-day moving average price of $3.45. The firm has a market capitalization of $316.61 million, a price-to-earnings ratio of -4.44 and a beta of 1.28.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its position in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after purchasing an additional 136,300 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after buying an additional 328,312 shares in the last quarter. BNP Paribas Financial Markets grew its position in AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after buying an additional 8,423 shares during the period. Lazard Asset Management LLC purchased a new position in AC Immune in the first quarter valued at $30,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after acquiring an additional 7,400 shares during the period. Institutional investors and hedge funds own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.